Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Seed amplification assays (SAAs) for misfolded α-synuclein (syn) have shown inconsistent results in multiple system atrophy (MSA).
Objective: The objective of this study was to compare a novel syn SAA (synSAA) that distinguishes between Lewy body disease (LBD) and MSA syn-seeds (Amprion-SAA) with an LBD-specific synSAA (IRCCS Istituto delle Scienze Neurologiche di Bologna [ISNB]-SAA).
Methods: We applied both assays to cerebrospinal fluid samples from 114 patients with MSA, 49 patients with Parkinson disease (PD), 40 patients with progressive supranuclear palsy (PSP), and 46 controls.
Results: Amprion-SAA detected type 2 ("MSA-type") syn-seeds in 101 (88.6%) MSA, 3 (6.1%) PD, 4 (10.0%) PSP, and 6 (13.0%) control participants, and type 1 ("LBD-type") syn-seeds in 39 (79.6%) PD, 3 (2.6%) MSA, and 1 (2.5%) PSP participant. ISNB-SAA detected LBD-specific syn-seeds in 40 (81.6%) PD, 4 (3.5%) MSA, and none of the PSP or control participants.
Conclusions: Amprion-SAA, performed at ISNB, uniquely discriminated MSA from both PD and PSP participants with good accuracy. However, it showed lower specificity than ISNB-SAA, primarily related to the type 2 profile. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mds.70017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Updates on Parkinson's Disease.
Neuropsychiatr Dis Treat
September 2025
Department of Radiology, No. 926 Hospital, Joint Logistics Support Force of PLA, Kaiyuan, Yunnan, 661699, People's Republic of China.
Parkinson's disease (PD) represents a progressive neurodegenerative disorder with escalating global burden, with mechanistic studies revealing α-synuclein propagation through gut-brain axis, mitochondrial defects, and neuroinflammatory cascades driven by genetic-environmental interplay. Recent advancements in diagnostic paradigms have successfully combined α-synuclein seed amplification assays with multimodal neuroimaging techniques, achieving an impressive diagnostic accuracy of 92% during the prodromal stages of disease. Phase II trials highlight disease-modifying potential of α-synuclein-targeting immunotherapies (40% reduction in motor decline) and LRRK2 kinase inhibitors showing blood-brain barrier penetration.
View Article and Find Full Text PDFα-Synuclein Seed Amplifications Assay in a Cohort With Cognitive Impairment: Performance and Interactions With CSF and Plasma Biomarkers.
Neurology
October 2025
Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic de Barcelona, Fundació Recerca Clínic Barcelona-IDIBAPS, Spain.
Background And Objectives: α-Synuclein seed amplification assays (αSAAs) can improve the diagnosis of synucleinopathies and detect α-synuclein (αSyn) copathology in vivo in clinical practice. We aimed to evaluate the diagnostic performance of αSAA for detecting αSyn in CSF for diagnosing dementia with Lewy bodies (DLB) in a clinical cohort of cognitively impaired individuals. We explored how the coexistence of Alzheimer disease (AD) and αSyn pathology influences biomarker levels and clinical profiles.
View Article and Find Full Text PDFProdromal Lewy Body Symptoms and α-Synuclein Seeding in Idiopathic Olfactory Dysfunction.
Mov Disord Clin Pract
September 2025
Department of Neurology, Danish Dementia Research Centre, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Background: Early identification of pathological α-synuclein deposition (αSynD) may improve understanding of Lewy body disorder (LBD) progression and enable timely disease-modifying treatments.
Objectives: We investigated αSynD using a seed amplification assay and assessed prodromal LBD symptoms in individuals with idiopathic olfactory dysfunction (iOD).
Methods: In this cross-sectional, case-control study, we included iOD participants and normosmic healthy controls (HC) aged 55 to 75 years without diagnoses of dementia with Lewy bodies, Parkinson's disease (PD), or other major neurological disorders.
Clinical and Biofluid Biomarkers of Sleep Dysfunction in Parkinson's Disease.
Sleep Med Clin
September 2025
Centre for Neurology, Academic Specialist Centre, Stockholm Health Services, Solnavägen 2, 11365 Stockholm, Sweden; Department of Clinical Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden; Department of Neurology, Karolinska University Hospital, Bioclinicum J5:20, Stockholm 17164, Swede
Parkinson's disease is a neurodegenerative disorder with an increasing prevalence worldwide. The development of disease-modifying therapies remains a critical priority; however, early intervention is limited by the paucity of robust biomarkers for the prodromal stage. Sleep disturbances-particularly isolated rapid eye movement sleep behavior disorder (iRBD)-are emerging as key clinical markers of prodromal synucleinopathy, offering opportunities for early detection and risk stratification.
View Article and Find Full Text PDFAlzheimer's disease traits in Parkinson's disease without α-synuclein seeding.
Alzheimers Dement
May 2025
Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
Introduction: The α-synuclein (αSyn) seed amplification assay (αSyn-SAA) is an accurate tool to detect αSyn seeds in patients with Parkinson's disease (PD). However, a minority of clinically diagnosed PD patients are negative for αSyn.
Methods: The αSyn-SAA was performed in cerebrospinal fluid (CSF) of individuals with PD (n = 93), multiple system atrophy (MSA, n = 26), progressive supranuclear palsy (PSP, n = 18), corticobasal syndrome (n = 3), and healthy controls (n = 29).